AgomAb shares surge 131.58% after-hours after closing $200M IPO on Nasdaq.

AgomAb Therapeutics (AGMB) surged 131.58% in after-hours trading following the announcement of its successful initial public offering. The company closed its IPO on February 9, 2026, issuing 12.5 million American Depositary Shares at $16.00 per ADS, raising approximately $200 million in gross proceeds before underwriting fees. The ADSs began trading on the Nasdaq Global Select Market on February 6 under the ticker “AGMB,” with J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen serving as joint book-running managers. The offering, declared effective by the SEC on January 30, provided capital to advance its pipeline of disease-modifying therapies for chronic fibrotic diseases. The significant post-IPO rally reflects investor optimism about AgomAb’s focus on high-unmet-need indications and the company’s strategic positioning in the biopharma sector.